Predictive Diagnostics Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMCD1123 | Last Updated On: Jun 22 2022 | Available Formats

> Global Predictive Diagnostics Market Expected to reach a high CAGR By 2029: DataM Intelligence

Global Predictive Diagnostics Market is segmented By Type (Presymptomatic, Predispositional), By Application (Cardiovascular Diseases, Neurological Diseases, Genetic Diseases, Oncology, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global "Predictive Diagnostics Market" is expected to reach at a high CAGR during the forecast period (2022-2029).

  • Predictive diagnostics are genetic tests that can determine a person’s susceptibility to certain diseases. Predictive diagnostics consists of identifying the presence or inheritance of any mutated gene different from other members of the family. These tests help in the identification of genetic disorders in an individual that show no features of the disorder. Predictive Diagnostics can predict whether a person will develop a particular disease or not much before the symptoms appear and can, therefore, help in precaution, preventive measures, and early treatment.
  • The development of new diagnostic biomarkers for different diseases are targeting the prevention of common human pathologies. Preventive diagnostic tests have led to the discovery of optimal treatment planning methods and personalized medicines for individuals, thus reducing healthcare costs. Predictive diagnostics are a novel approach in molecular biologics.

Market Dynamics 

  • The market is driven by a rise in prevalence of chronic denerative diseases such as cardiovascular, autoimmune, and neurodegenerative diseases and an increase in various types of cancer especially breast cancer, need for detection of various genetic disorders at the earliest stage possible.
  • Breast cancer can be predicted in advance with the help of predictive diagnostics, and a large number of fatalities can be avoided. According to the World Health Organization (WHO), breast cancer is the second most commonly diagnosed cancer with an estimated amount of 1.8 million cases in 2018 and over 530,000 deaths worldwide among women. Predictive diagnostics can efficiently predict the presence of BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two) that can develop breast cancer. According to, women who have a BRCA1 mutation or BRCA2 mutation (or both) can have up to a 72% risk of being diagnosed with breast cancer during their lifetimes.
  • Predictive diagnostics can help protect the health of people who are at high genetic risk for diseases by early diagnosis and treatment. With the help of these tests, physicians can make suitable treatment decisions for accurate diagnostic based on the progression of the disease and likely treatment response. Physicians can even evaluate the risk of disease transmission to the patient‘s offspring.
  • Less reliability of biomarkers for identification of chronic degenerative diseases and lack of expertise in predictive diagnostics testing are going to restrain the market in the forecast period.

Market Segmentation

  • The global predictive diagnostics market can be segmented by type as Presymptomatic Testing and Predispositional Testing and by application as Cardiovascular Diseases, Neurological Diseases, Genetic Diseases, Oncology, and Others.
  • Predictive testing is used to find gene changes that increase a person's likelihood of developing a particular disease. Presymptomatic tests provide information about the risks of developing a specific disease. Such information is useful in decisions regarding lifestyle and healthcare. If an individual has a family history of a genetic condition, get presymptomatic tests to show if there is a risk of developing that condition. For instance, this type of test may be useful for identifying the risks of certain types of colorectal cancer and breast cancer.

Geographical Share

  • Geographically, the global predictive diagnostics market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East, and Africa.
  • North America and Europe are the major dominant markets for predictive diagnostics and are expected to grow over the period of forecast. The market in both regions are growing due to an increase in the prevalence of genetic, chronic, and neurodegenerative disorders including cystic fibrosis and Alzheimer's disease, and several cancer types. According to the Cystic Fibrosis Foundation Patient Registry in the US, more than 30,000 people are living with cystic fibrosis. A high level of awareness among the population and the presence of many large companies making investments in developed nations are expected to boost the market for predictive diagnostics. 

Market Competition

Some of the major key players in the market are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V.

  • In March 2019, Myriad Genetic Laboratories, Inc. announced the addition of six new genes to the Myriad myRisk Hereditary Cancer Panel namely AXIN2, MSH3, RPS20, GALNT12, NTHL1, and RNF43.
  • In December 2018, BaseHealth launched the first predictive analytics platform that mines clinical laboratory data, enabling healthcare organizations (HCOs) to improve population health, boost quality scores, and optimize risk adjustment.
  • In October 2018, Myriad Genetics announced that the FDA had approved its BRACAnalysis CDx to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP inhibitor, Talzena (talazoparib).
  • In October 2018, Predictive Technology Group launched a unique endometriosis risk test at the 74th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo in Denver, Colorado.
  • In March 2018, the U.S. FDA approved first direct-to-consumer test for the BRCA genes from 23andMe.
  • In March 2018, Proteomics International launched PromarkerD an advanced and accurate proteomics algorithm test system to predict the onset of kidney disease.

Trending Topics

In Vitro Diagnostics Market

Morgue Refrigerator Market

Early Toxicity Testing Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!